Table 2 Bone mineral density change among patients with schizophrenia and healthy individuals.
From: Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia
Controls | Non-clozapine antipsychotics | Clozapine | P value | |
|---|---|---|---|---|
DEXA Z score, overall | (N = 44) | (N = 69) | (N = 42) | |
Baseline, mean (SD) | 0.28 (1.09) | −0.28 (1.14) | 0.38 (1.45) | 0.008 |
Endpoint, mean (SD) | 0.42 (1.08) | −0.44 (0.96) | 0.41 (1.49) | <0.001‡ |
Difference, mean (SD) | 0.16 (0.47) | −0.16 (0.66) | 0.03 (0.64) | 0.015‡ |
DEXA Z score, 1 year follow up | (N = 48) | (N = 29) | ||
Baseline, mean (SD) | — | −0.54 (1.10) | 0.16 (1.49) | 0.017 |
Endpoint, mean (SD) | — | −0.68 (0.88) | 0.09 (1.47) | 0.006 |
Difference, mean (SD) | — | −0.13 (0.56) | −0.08 (0.70) | 0.808‡ |
DEXA Z score, 3 year follow up | (N = 44) | (N = 22) | (N = 13) | |
Baseline, mean (SD) | 0.28 (1.09) | 0.28 (1.15) | 0.88 (1.29) | 0.228 |
Endpoint, mean (SD) | 0.42 (1.08) | 0.09 (0.93) | 1.13 (1.29) | 0.052‡ |
Difference, mean (SD) | 0.16 (0.47) | −0.21 (0.87) | 0.25 (0.41) | 0.039‡ |
